MINIREVIEW

Prostaglandins as Putative Neurotoxins in Alzheimer's Disease (44323)

KEDAR N. PRASAD,[1] ALICIA R. HOVLAND, FRANCISCO G. LA ROSA, AND PETER G. HOVLAND

Center for Vitamins and Cancer Research, Department of Radiology, University of Colorado Health Sciences Center, School of Medicine, Denver, Colorado 80262-0228

Abstract. Chronic inflammatory reactions in the brain appear to be one of the primary etiological factors in the pathogenesis of Alzheimer's disease (AD). This is supported by the fact that the secretory products of inflammatory reactions, which include cytokines, complement proteins, adhesion molecules, and free radicals, are neurotoxic. We have recently reported that prostaglandins (PGs), which are also released during inflammatory reactions, cause rapid degenerative changes in differentiated murine neuroblastoma cells (NB) in culture. PGA_1 is more effective than PGE_1. Similar observations were made in a primary culture of fetal rat hippocampal cells. Epidemiological and clinical studies on AD also support the involvement of PGs in neuronal degeneration. Thus, we propose a hypothesis that PGs are one of the major extracellular signals that initiate neuronal degeneration, which is mediated by intracellular signals such as the β-amyloid peptide (Aβ) and ubiquitin, since the levels of these proteins are increased by PG treatment. We further suggest that adenosine 3', 5'-cyclic monophosphate (cAMP) is one of the factors that regulate the levels of both Aβ and ubiquitin in NB cells. Increases in the level of Aβ in NB cells following an elevation of intracellular cAMP levels appear to be due to an increase in the rate of processing of the amyloid precursor protein (APP) rather than an increase in the expression of APP. The mechanisms underlying Aβ-induced neuronal degeneration have been under intense investigation, and several mechanisms of action have been proposed. We postulate that PG-induced elevation of Aβ may lead to an increased binding of Aβ to the 20S proteasome, resulting in a reduction of 20S proteasome-mediated degradation of ubiquitin-conjugated proteins. This is predicted to lead to an increase in an accumulation of abnormal proteins, which ultimately contribute to neuronal degeneration and death. Based on our hypothesis and on studies published by others, we propose that a combination of nonsteroidal anti-inflammatory drugs, which inhibit the synthesis of PGs, and antioxidant vitamins, which quench free radicals and both of which have been recently reported to be of some value in AD treatment when used individually, may be much more effective in the prevention and treatment of AD than the individual agents alone. [P.S.E.B.M. 1998, Vol 219]

It is estimated that 5%–11% of the U.S. population over the age of 65 and approximately 47 percent of the population over the age of 85 suffer from Alzheimer's Disease (AD) (1–3). Approximately 2–4 million Americans have been diagnosed with AD, many of whom require institutional care at a cost that is estimated to exceed 50 billion dollars.

The involvement of inflammatory reactions in the pathogenesis of AD was first noted by Alois Alzheimer himself. Later, it was shown that the products of inflamma-

tory reactions, such as cytokines (4–7), complement proteins (8–16), free radicals (17–24), and adhesion molecules (14, 25–28), are neurotoxic. Therefore, these may represent extracellular signals that initiate neuronal degeneration in AD through several intracellular signals. Among the intracellular signals, β-amyloid (Aβ) (29–33), ubiquitin (34, 35), and presenilins (PS) I and II (36, 37) are considered to be important in initiating neuronal degeneration. Several reviews on the involvement of Aβ, in particular, have been published (29–33). We have recently reported that prostaglandins (PGs), which are also produced and secreted during inflammatory reactions, induce rapid degeneration in differentiated murine neuroblastoma (NB) cells in culture (38, 39). The purpose of this minireview is to discuss experimental, clinical, and epidemiological data that support our hypothesis that PGs may also be one of the critical external signals that initiate degeneration of nerve cells in AD.

Prostaglandins E_1 and A_1 Induce Differentiation and Degeneration in Cultured Nerve Cells

In the early 1970s, we were the first to discover that PGE_1, a stimulator of adenylate cyclase, induces terminal differentiation in NB cells in culture by increasing the intracellular levels of cAMP (40). Subsequently, it was found that both the PGE and PGA series are effective inducers of differentiation, whereas other PGs, such as PGF2α, are not (41). Other agents that elevate intracellular levels of cAMP such as 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone (RO20-1724), an inhibitor of cyclic nucleotide phosphodiesterase, and dibutyryl cAMP, an analog of cAMP, produce similar effects on differentiation of NB cells (41). In addition to inducing NB cell differentiation, PGE_1 was found to inhibit the growth of certain non-neuronal tumor cells in culture (42–44). The neurotoxic effect of PGE_1 was discovered accidentally. In an effort to generate a 100% terminally differentiated NB cell culture for neural transplant studies, we used either a polar carotenoid, initially referred to as β-carotene (45), or α-tocoperol succinate (α-TS, vitamin E) in combination with either RO20-1724 or PGE_1. The number of terminally differentiated cells increased from 40%–60% to over 95% at 3 days after each of the above treatments (46). In order to assess the viability of differentiated NB cells in vitro after achieving a maximal level of differentiation, the cultures treated with RO20-1724 plus a polar carotenoid or PGE_1 plus a polar carotenoid were observed for an additional 3 days (Table I). The results showed that almost all of the differentiated NB cells treated with PGE_1 were either dead or degenerated. In contrast, most of the differentiated cells treated with RO20-1724 were still viable (38–46). This suggested that PGE_1 could act as a neurotoxin for differentiated NB cells. To substantiate this finding, NB cells were maximally differentiated by treatment with either RO20-1724 plus the polar carotenoid or dibutyryl cAMP plus the polar carotenoid for a period of 3 days prior to treatment with PGE_1. Marked degenerative changes were

Table I. Effects of Prostaglandins (PG) on Differentiation and Degeneration of Neuroblastoma (NB) Cells in Culture

Treatment	Time	Percentage of differentiation	Percentage of degeneration
RO20-1724 + PC	4 days	92 ± 2	5 ± 2
PGE_1 + PC	4 days	95 ± 3	41 ± 3
PGA_1 + PC	4 days	77 ± 4	72 ± 3
RO20-1724 + PC	6 days	91 ± 2	12 ± 2
PGE_1 + PC	6 days	90 ± 3	60 ± 3
PGA_1 + PC	6 days	0	100

Note. RO20-1724 (200 μg/ml); Polar Carotenoid (PC, 20 μg/ml); Prostaglandin E_1 (PGE_1, 10 μg/ml); Prostaglandin A_1 (PGA_1, 2.5 μg/ml) (39).

seen in the differentiated NB cells treated with PGE_1 as early as 1 day after treatment. At 3 days after PGE_1 treatment, most of the differentiated cells were either dead or degenerated (39). When similar experiments were performed with PGE_2, PGA_1, or PGA_2, it was found that the PGA series was more effective in causing neuronal degeneration than the PGE series (39). In order to establish whether PGE_1 and PGA_1 induce degeneration in hippocampal neurons, which are the primary targets of degeneration in AD, the effect of these PGs on neuronal degeneration in these cells was studied. Results showed that PGE_1 and PGA_1 induce apoptosis in a primary culture of fetal rat hippocampal cells in a manner similar to that observed in differentiated NB cells. Similarly, PGA_1 was also found to be more effective than PGE_1 in this primary culture (Clarkson ED, La Rosa FG, and Prasad KN, unpublished observations).

Elevation of β-Amyloid and Ubiquitin Protein Levels by PGE_1 in NB Cells

The levels of both Aβ (29–33) and ubiquitin (34, 35) appear to be elevated in the AD brain. Therefore, a role for each in neurodegeneration has been proposed. In addition, a role for the mutated presenilin genes (PS), PSI, and PSII, has been proposed for familial AD (36, 37). However, the mechanisms by which these proteins either individually or in combination cause degeneration of nerve cells are not well understood. Currently, one of the major areas of investigation for AD research is to determine the mechanisms underlying the generation and secretion of elevated levels of the amyloidogenic Aβ peptide. A recent hypothesis is that the mutant PSI and PSII proteins form a complex with APP (33). This PS-APP complex, in turn, interacts with the intracellular organelles containing proteolytic enzymes. The result is increased proteolysis of APP to form Aβ which, subsequently, is secreted into the extracellular spaces. Indeed, PS-APP complexes have been found to form Aβ by cleavage that is facilitated by the γ secretase enzyme (47). This enzyme is located primarily in the endoplasmic reticulum (48), suggesting the possibility that Aβ is secreted through the endoplasmic reticulum to the extracellular

spaces of the AD brain. The mechanisms underlying Aβ-induced neuronal degeneration are as yet unknown; however, some indirect mechanisms have been proposed. For example, Aβ upregulates the synthesis of IL1 and other cytokines (49, 50). Conversely, IL1β enhances the production of APP, which then becomes available for generating increased amounts of Aβ (51–54). Similarly, aggregates of Aβ activate C1q, a complement protein, and C1q enhances Aβ aggregation (16). Thus, two products of inflammatory reactions, cytokines and complement proteins, are known to interact with Aβ in a way that enhances their respective levels and/or activity.

The relationship between PGs, which are also major secretory products of inflammatory reactions, and Aβ in nerve cells has never been studied. Recently, we have found that PGE_1 markedly increases the level of Aβ as early as 24 hr after treatment (39). Since this was initially determined by immunostaining the NB cells with a primary antibody whose epitope lies within the N-terminal 14 amino acids of

Figure 1. Photomicrographs of immunostained mouse neuroblastoma (NB) cells with a polyclonal antibody against the first 14 amino acids of the β-amyloid peptide (A^B) (Chemicon, Temecula, CA) at 4 days after treatment with prostaglandins (PGs). Control undifferentiated NB cells exhibited cytoplasmic staining (Panel b). Cells not treated with the primary antibody did not stain (Panel a). Most of the differentiated NB cells induced by RO20-1724 (200 µg/ml) plus a polar carotenoid (PC) (20 µg/ml), originally referred to as β-carotene (45), showed increased cytoplasmic staining, and neurites were also stained (Panels c and d). Differentiated NB cells induced by PGE_1 (10 µg/ml) plus a PC exhibited more cytoplasmic staining with intense fluorescent spots in some cells (Panel e) than that found in RO20-1724 treated cells (Panels c and d). Most of the degenerated NB cells in cultures treated with PGA_1 (2.5 µg/ml) plus a PC showed a marked decline in cytoplasmic fluorescent staining (Panel f). Magnification 400×. (39)

the Aβ peptide that is common to full-length APP (Fig. 1), it was not clear whether the enhancement in immunostaining was due to an increase in the levels of APP or Aβ. Therefore, an additional study was done with an antibody whose epitope lies within amino acids 44–63 of APP and, thus, is specific only for APP. Results showed that PGE_1 failed to yield a significant increase in the level of APP in NB cells (La Rosa FG and Prasad KN, unpublished observations). These data suggested that the increase in intensity of the fluorescent signal in NB cells following treatment with PGE_1 was primarily due to an increase in the processing of APP that yields the Aβ peptide rather than an increase in APP levels. We also showed that R020-1724 increases Aβ levels by a mechanism similar to that observed with PGE_1. Since both of these agents increase the intracellular level of cAMP within 15 min after treatment (41), we propose that cAMP may be one of the factors involved in the regulation of APP processing that leads to increased levels of Aβ production in NB cells. This is in contrast to observations made in astrocytes, glioma, and neuroblastoma X glioma hybrid cells, in which cAMP upregulates the level of APP mRNA (55, 56). However, it remains uncertain whether an elevation of cAMP in these cells leads to either increased levels of APP or an increase in production of Aβ from APP, since corresponding protein levels were not measured. These results suggest that an elevation of cAMP increases the level of APP in glia cells, whereas we show that cAMP increases the level of Aβ, but not APP, in NB cells. The increased accumulation of Aβ is associated with PG-induced degeneration of NB cells; however, the degenerated cells do not produce Aβ (39). Therefore, we argue that Aβ may be the cause of cell death rather than a byproduct of cell death. However, the fact that the degenerative changes seen with PGA_1/PGE_1 are much more rapid than those that result from R020-1724 treatment indicates that PG-specific factors other than cAMP are involved. Thus, PGs released during inflammatory reactions may represent another external signal for neuronal degeneration that initiates a series of alterations in intracellular signals such as Aβ.

Another protein proposed to have a role in neuronal degeneration in AD is ubiquitin (34, 35), a protein involved in the normal processing and turnover of proteins. However, its mechanism of action in neurodegeneration is not known. In addition, the relationship between ubiquitin and Aβ, if any, has not been defined adequately. Finally, the regulation of intracellular ubiquitin levels in nerve cells is not known. Recently, we have observed that both PGA_1 and PGE_1 increase the levels of ubiquitin in NB cells as determined by immunostaining of the cells with both monoclonal and polyclonal antibodies against ubiquitin (Fig. 2). The increase in ubiquitin levels coincides with the observed increase in Aβ levels. R020-1724 also increases the level of ubiquitin in a manner similar to that observed with PGE_1 (57). Therefore, we suggest that cAMP may be one of the primary factors involved in the regulation of ubiquitin levels in NB cells as well. Since the levels of both Aβ and ubiquitin increase at

Figure 2. Photomicrographs of immunostained mouse neuroblastoma (NB) cells with a primary antibody to ubiquitin at 4 days after treatment with prostaglandins (PGs). Immunostaining was done with a polyvalent rabbit anti-ubiquitin antibody (Sigma, St. Louis, MO). Control cells showed primarily cytoplasmic staining (Panel B), whereas cells without the primary antibody did not stain (Panel A). All differentiated NB cells induced by RO20-1724, an inhibitor of cyclic nucleotide phosphodiesterase, showed increased cytoplasmic fluorescent staining and contained fluorescent neurites. Differentiated NB cells induced by PGE_1 (10 μg/ml) plus a polar carotenoid (PC) (20 μg/ml), originally referred to as β-carotene (45), exhibited a more intense cytoplasmic fluorescent staining (Panel D) than that found in RO20-1724 treated cells (Panel C). The degenerated NB cells induced by PGA_1 (2.5 μg/ml) plus PC showed a marked decline in cytoplasmic staining (Panel E). Magnification 400×. (39)

about the same time following elevation of intracellular levels of cAMP, we also propose that their regulation may be coupled (39).

Interestingly, the level of ubiquitin expression appears to be higher than that of Aβ in differentiated NB cells (39). This observation taken together with the fact that ubiquitin binds to the 20S proteasome *in vitro* (58), an enzyme that degrades ubiquitin-conjugated proteins (59), has led us to propose a hypothesis regarding the relationship between ubiquitin and Aβ in causing neuronal degeneration. We suggest here that PG-induced elevation of Aβ may cause increased binding of Aβ with the 20S proteasome and thereby reduce degradation of ubiquitin-conjugated proteins. This is predicted to lead to an increased accumulation of ubiquitin-conjugated proteins which, ultimately, leads to neuronal death. Indeed, increased levels of ubiquitin-conjugated proteins have been observed in AD brains (60–63). A recent study on non-neuronal cells demonstrated that apoptosis coincided with an accumulation of ubiquitinated proteins in these cells (64). The following evidence further supports our hypothesis and could explain neuronal degeneration in AD: a) increases in intracellular deposition of Aβ correlates with cell death in AD brains (65); b) Aβ peptides are associated with intracellular neurofibrillary tangles (66,

67); c) using transient transfection assays in COS cell intracellular expression of Aβ results in the formation of amyloid-like fibrils leading to cell death (68); and d) increased accumulation of intracellular Aβ occurs in neurons before the appearance of extracellular deposits of Aβ in aged monkey (69) and dog (70) brains.

Epidemiological and Clinical Studies

The involvement of PGs in AD is supported by clinical and epidemiological studies. For example, nonsteroidal anti-inflammatory drugs (NSAIDs), which inhibit PG synthesis, reduce the rate of deterioration of cognitive behavior in AD patients (71–77). In addition, rheumatoid arthritis patients who are on high doses of anti-inflammatory drugs have a reduced incidence of AD (78–81). Thus, NSAIDs or any other drugs that inhibit PG synthesis in the CNS may represent agents that have a sound experimental, clinical, and epidemiological basis for use in the prevention of AD among high risk groups and in the treatment of AD. Since PGs increase the levels of Aβ in NB cells and since increased binding of Aβ with the 20S proteasome can occur possibly leading to increased levels of ubiquitin-conjugated proteins, an agent that can prevent the binding of Aβ with

the 20S proteasome, therefore, could also be useful in preventing degeneration of neurons in AD brains.

Free radicals are also released during inflammatory reactions; therefore, antioxidant vitamins may also be useful in the prevention among high-risk populations and in the treatment of AD. Indeed, the use of a high dose of a vitamin E supplement was recently found to produce some beneficial effects in patients with moderately severe AD (82). Based on the above studies we suggest that a combination of NSAIDs, which inhibit PG synthesis, and antioxidant vitamins, which quench free radicals, may be much more effective in the prevention and treatment of AD than either of the individual agents alone.

1. Pfeffer RI, Afifi AA, Chance JM. Prevalence of Alzheimer's disease in a retirement community. Am J Epidemiol 125:420–436, 1987.
2. Schoenberg BS, Kokmen E, Okazaki H. Alzheimer's disease and other dementing illnesses in a defined United States population: Incidence rates and clinical features. Ann Neurol 22:724–729, 1987.
3. Evans DA, Frankenstein HH, Albert MS. Prevalence of Alzheimer's disease in a community population of older persons higher than previously reported. JAMA 262:2551–2556, 1989.
4. Anderson K, Launer LJ, Ott A, Hoes AW, Breteler MMB, Hofman A. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease. Neurology 45:1441–1445, 1995.
5. Rogers J, Singer RH, Luber-Narod J, Bassell GJ. Neurovirologic and neuroimmunologic considerations in Alzheimer's disease. Neuroscience 12a:944, 1986.
6. Shalit F, Sredni B, Stern B, Stern L, Kott E, Huberman M. Elevated interleukin-6 secretion levels by mononuclear cells of Alzheimer's patients. Neurosci Lett 174:130–132, 1994.
7. Sharif SF, Hariri RJ, Chang VA, Barie PS, Wang RS, Ghajar JB. Human astrocyte production of tumor necrosis factor-α, interleukin-1 β and interleukin-6 following exposure to lipopolysaccharide endotoxin. Neurol Res 15:109–112, 1993.
8. Rogers J, Lue L-F, Brachova L, Webster S, Schultz J. Inflammation as a response and a cause of Alzheimer's pathophysiology. Dementia 9:133–138, 1995.
9. Kuby J. Immunology. New York: W.H. Freeman and Company, pp393–411, 1994.
10. Rogers J, Cooper NR, Webster S, Schultz J, McGreer PL, Styren SD, Civin WH, Brachova L, Bradt B, Ward P, Lieberburg I. Compliment activation by β-amyloid in Alzheimer's disease. Proc Natl Acad Sci USA 89:10016–10020, 1992.
11. Eikelenboom P, Stam FC. Immunoglobulins and compliment factors in senile plaques. Acta Neuropathol 57:239–242, 1982.
12. Eikelenboom P, Stam FC. An immunohistochemical study on cerebral and senile plaque amyloid in Alzheimer's disease dementia. Virch Arch B (Cell Pathol) 47:17–25, 1984.
13. Eikelenboom P, Hack DE, Rozenmuller JM, Stam FC. Compliment activation in amyloid plaques in Alzheimer's disease but not scrapie-affected mice are closely associated with a local inflammatory process. Virch Arch B (Cell Pathol) 60:329–336, 1989.
14. Eikelenboom P, Zhan SS, Kamphorst W, Van der Alk P, Rozenmuller JM. Cellular and substrate adhesion molecules (integrins) and their ligands in cerebral amyloid plaque in Alzheimer's disease. Virch Arch B (Cell Pathol) 424:421–427, 1994.
15. Lue L-F, Rogers J. Full compliment activation fails to diffuse plaques of the Alzheimer's disease cerebellum. Dementia 3:308–313, 1992.
16. Webster S, O'Barr S, Rogers J. Enhanced aggregation and β structure of amyloid β peptide after co-incubation with C1q. J Neurosci Res 39:448–456, 1994.

17. Anderton B. Free radicals on the mind: Hydrogen peroxide–mediated amyloid β protein toxicity. Hum Exp Toxicol 13:719a, 1994.
18. Chen L, Richardson JS, Caldwell JE, Ang LC. Regional brain activity of free radical defense enzymes in autopsy samples from patients with Alzheimer's disease and from nondemented controls. Int J Neurosci 75:83–90, 1994.
19. Evans PH. Free radicals in brain metabolism and pathology. B Med Bull 49:577–587, 1993.
20. Gotz ME, Kunig G, Riederer P, Youdim MB. Oxidative stress: Free radical production in neural degeneration. Pharmacol Ther 64:37–122, 1994.
21. Olanow CW, Arendash GW. Metals and free radicals in neurodegeneration. Curr Opin Neurol 7:548–558, 1994.
22. Richardson JS, Subbarao KV, Ang LC. On the possible role of iron-induced free radical peroxidation in neural degeneration in Alzheimer's disease. Ann NY Acad Sci 64:326–327, 1992.
23. Smith MA, Sayre LM, Monnier VM, Perry G. Radical ageing in Alzheimer's disease. Trends Neurosci 18:172–176, 1995.
24. Harman D. Free radical theory of aging: Alzheimer's disease and pathogenesis. Age 18:97–119, 1995.
25. Frohman EM, Frohman TC, Gupta S, de Fougerolles A, van den Noort S. Expression of intracellular adhesion molecule-1 (ICAM-1) in Alzheimer's disease. J Neurosci 106:105–111, 1991.
26. Verbeek MM, Otte-Holler I, Westphal JR, Wesseling P, Ruiter DJ, de Waal RM. Accumulation of intracellular adhesion molecule-1 in senile plaques in brain tissue of patients with Alzheimer's disease. Am J Pathol 144:104–116, 1994.
27. Rozenmuller JM, Eikelenboom P, Pals ST, Stam FC. Microglia cells around amyloid plaques in Alzheimer's disease express leukocyte adhesion molecules of the LFA-1 family. Neurosci Lett 101:228–292, 1989.
28. Rosenman SJ, Shrikant P, Dubb L, Benveniste EN, Ransohoff RM. Cytokine-induced expression of vascular cell adhesion molecule-1 (VCAM-1) by astrocytes and astrocytoma cell lines. J Immunol 154:1888–1889, 1995.
29. Yankner BA, Mesulam MM. β-amyloid and the pathogenesis of Alzheimer's disease. New Eng J Med 325:1849–1857, 1991.
30. Hardy T, Allsop D. Amyloid deposition as the cerebral even in the etiology of Alzheimer's disease. Trend Pharmacol Sci 12:383–388, 1991.
31. Joachim CL, Selkoe DJ. The seminal role of β-amyloid is the pathogenesis of Alzheimer's disease. Alzheimer Dis Assoc Disord 6:7–34, 1992.
32. Selkoe DJ. Cell biology of the amyloid-β protein precursor and the mechanism of Alzheimer's disease. Annu Rev Cell Biol 10:373–403, 1994.
33. Dewzi NN, Singer SJ. Genetic clues to Alzheimer's disease. Science 271:159–160, 1996.
34. Wang GP, Khatoon S, Iqbal K, Grunke-Iqbal I. Brain ubiquitin is markedly elevated in Alzheimer's disease. Brain Res 566:146–151, 1991.
35. Kudo T, Iqbal K, Ravid R, Swaab DF, Grundke-Iqbal I. Alzheimer's disease: Correlations of cerebrospinal fluid and brain ubiquitin levels. Brain Res 649:1–7, 1994.
36. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375:754–760, 1995.
37. Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, Liang Y, Chi H, Lin C, Holman K, Tsuda T, et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 376:775–778, 1995.
38. Prasad KN, Kentroti S, Edwards-Prasad J, Vernadakis A, Imam M, Carvalho E, Kumar S. Modification of the expression of adenosine 3',5'-cyclic monophosphate-induced differentiated functions in neuroblastoma cells by β carotene and d-α-tocopheryl succinate. J Am Coll Nutr 13:298–303, 1994.
39. Prasad KN, La Rosa FG, Prasad JE. Prostaglandins act as neurotoxin for differentiated neuroblastoma cells in culture and increase levels of ubiquitin and β-amyloid. In Vitro Cell Dev Biol 834:265–274, 1998.

40. Prasad KN. Morphological differentiation induced by prostaglandins in mouse neuroblastoma cells in culture. Nature New Biol 236:49–51, 1972.

41. Prasad KN. Differentiation of neuroblastoma cells: A useful model for neurobiology and cancer. Biol Rev 66:431–451, 1991.

42. Eisenbarth GS, Wellman DK, Lebovitz HE. Prostaglandin A_1 inhibition of chondrosarcoma growth. Biochem Biophys Res Commun 60:1302–1308, 1974.

43. Santoro MG, Benedetto A, Jaffe BM. Prostaglandin A_1 induces differentiation in Friend erythroleukemia cells. Prostaglandins 17:719–727, 1979.

44. Karmali RA. Prostaglandins and cancer. Prostaglandins Med 5:11–28, 1980.

45. Hazuka MB, Edwards-Prasad J, Newman F, Kinjie JJ, Prasad KN. β-carotene induces morphological differentiation and decreases adenylate cyclase activity in melanoma cells in culture. J Am Coll Nutr 9:143–149, 1990.

46. Prasad KN, Edwards-Prasad J, Kentroti S, Freed C. Production of terminally differentiated neuroblastoma cells for neural transplant studies. Res Neurobiol Neurosci 7:13–19, 1994.

47. Selkoe DJ, Xia W, Zhang J, Koo EH. In vivo interactions between amyloid precursor protein and presenilins. Soc Neurosci 23:2949, 1997.

48. Capell A, Wild-Bode C, Yamazaki T, Steiner H, Ihara Y, Haass C. Cleavage of amyloid β-peptide at amino acid 42 occurs within the endoplasmic reticulum. Soc Neurosci 23:293a, 1997.

49. Araufo DM, Cotman CW. β-Amyloid stimulates glia cells in vitro to produce growth factors that accumulate in senile plaques in Alzheimer's disease. Brain Res 569:141–145, 1992.

50. Gitter BD, Cox LM, Rydel RE, May PC. Amyloid β peptide potentiates cytokine secretion by interleukin-1 β-activated human astrocytoma cells. Proc Natl Acad Sci USA 92:10738–10741, 1995.

51. Buxbaum JD, Oishi M, Chen HI, Pinkas-Kramarski R, Jaffe EA, Gandy SE, Greengard P. Cholinergic agonists and interleukin-1 regulate processing and secretion of the Alzheimer's $β/A_4$ amyloid protein precursor. Proc Natl Acad Sci USA 89:10075–10078, 1992.

52. Forloni G, Demicheli F, Giorgi S, Bendotti C, Angeretti N. Expression of amyloid precursor protein mRNAs in endothelial, neuron, and glia cells: Modulation by interleukin-1. Mol Brain Res 16:128–134, 1992.

53. Goldgaber D, Harris HW, Hla T, Maciag T, Donnelly RJ, Jacobsen JS, Vitek MP, Gajdusek DC. Interleukin 1 regulates synthesis of amyloid β-protein precursor mRNA in human endothelial cells. Proc Natl Acad Sci USA 86:7606–7610, 1989.

54. Gray CW, Patel AJ. Regulation of β-amyloid precursor protein isoform mRNAs by transforming growth factor β1 and interleukin-1β in astrocytes. Mol Brain Res 19:255–256, 1993.

55. Gegelashvili G, Bock E, Schousboe A, Linneman D. Two types of amyloid precursor protein (APP) mRNA in rat glioma cell lines: Upregulation via a cyclic AMP-dependent pathway. Brain Res Mol Brain Res 37:151–156, 1996.

56. Bourbonniere M, Shekarabi M, Nalbantoglu J. Enhanced expression of amyloid precursor protein in response to dibutyryl cyclic AMP is not mediated by the transcription factor AP-2. J Neurochem 68:909–916, 1997.

57. La Rosa FG, Kuma S, Prasad KN. Increased expression of ubiquitin during adenosine 3′,5′-cyclic monophosphate-induced differentiation of neuroblastoma cells in culture. J Neurochem 66:1845–1860, 1996.

58. Gregory L, Hainfield JF, Simon MN, Goldgaber D. Amyloid β protein binds the eukaryotic 20 S proteosome. Soc Neurosci 22:502a, 1996.

59. Rechsteiner M. Ubiqutin-mediated pathways for intracellular proteolysis. Annu Rev Cell Biol 3:1–10, 1987.

60. Mori H, Kondo L, Ihara Y. Ubiquitin and the enigma of intracellular protein degradation. Eur J Biochem 231:1–30, 1987.

61. Lowe J, Blanchard A, Morrell K, Lennox G, Reynolds L, Billet M, Landon M, Mayer J. Ubiquitin is a common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson's disease, Pick's disease, and Alzheimer's disease as well as Rosenthal fibres in cerebellar astrocytomas, cytoplasmic bodies in muscle, and Mallory bodies in alcoholic liver disease. J Pathol 155:9–15, 1988.

62. Kim H, Gearing M, Mirra SS. Ubiquitin-positive CA2/3 neurites in hippocampus coexist with cortical Lewy bodies. Neurology 45:1768–1770, 1995.

63. Morishima-kawashima M, Hasegawa M, Takio K, Suzuki M, Titani K, Ihara Y. Ubiquitin is conjugated with amino-terminally processed tau in paired helical filaments. Neuron 10:1151–1160, 1993.

64. Soldatenkov VA, Dritschilo A. Apoptosis of Ewing's sarcoma cells is accompanied by accumulation of ubiquitinated proteins. Cancer Res 57:3881–3885, 1997.

65. LaFerla FM, Tronsco JC, Strickland DK, Kawas CH, Jay G. Neuronal cell death in Alzheimer's disease correlates with apoE uptake and intracellular A β stabilization. J Clin Invest 100:310–320, 1997.

66. Grundke-Iqbal I, Iqbal K, George L, Tung YC, Kim KS, Wisniewski HM. Amyloid protein and neurofibrillary tangles coexist in the same neuron in Alzheimer disease. Proc Natl Acad Sci USA 86:2853–2857, 1989.

67. Perry G, Cras P, Siedlak SL, Tabaton M, Kawai M. β protein immunoreactivity is found in the majority of neurofibrillary tangles of Alzheimer's disease. Am J Pathol 140:283–289, 1992.

68. Maruyama K, Terakado K, Usami M, Yoshikawa K. Formation of amyloid-like fibrils in COS cells overexpressing part of the Alzheimer amyloid protein precursor. Nature (Lond) 347:566–569, 1990.

69. Martin LJ, Pardo CA, Cork LC, Price DL. Synaptic pathology and glial responses to neuronal injury precede the formation of senile plaques and amyloid deposits in the aging cerebral cortex. Am J Pathol 145:1358–1381, 1994.

70. Cummings BJ, Su JH, Cotman CW, White R, Russell MJ. β-Amyloid accumulation in aged canine brain: A model of early plaque formation in Alzheimer's disease. Neurobiol Aging 14:547–560, 1993.

71. McGeer PL, McGeer EG, Rogers J, Sibley J. Anti-inflammatory drugs and Alzheimer's disease. Lancet 335:1037, 1990.

72. Lucca U, Tettamanti M, Forloni G, Spagnoli A. Nonsteroidal anti-inflammatory drug use in Alzheimer's disease. Biol Psychiatry 36:854–856, 1994.

73. Rogers J, Kirby LC, Hempelman SR, Berry DL, McGreer PL, Kaszniak AW, Zalinski J, Cofield M, Mansukhani L, Wilson P, Kogan F. Clinical trial of indomethacin in Alzheimer's disease. Neurology 43:1609–1611, 1993.

74. Breitner JCS, Gau BA, Welsh KA, Plassman BL, McDonald WM, Helmas MJ, Anthony JC. Inverse association of anti-inflammatory treatments and Alzheimer's disease. Neurology 44:227–232, 1994.

75. Breitner JCS, Welsh KA, Helms MJ, Gaskell PC, Gau BA, Roses AD, Pericak-Vance MA, Sunders AM. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H_2 blocking drugs. Neurobiol Aging 16:523–530, 1995.

76. Broe GA, Henderson AS, Creasey H, McCusker E, Korten HE, Jorm AF, Longley W, Anthony JC. A case-control study of Alzheimer's disease in Australia. Neurology 40:1698–1707, 1990.

77. Graves AB, White E, Koepsell TD, Reifler BV, Van Belle G, Larson EB, Raskind M. A case-control study of Alzheimer's disease. Ann Neurol 28:766–774, 1990.

78. Jenkinson MI, Bliss MR, Brain AT, Scott DL. Rheumatoid arthritis and senile dementia of the Alzheimer's type. Br J Rheumatol 28:86–87, 1989.

79. Li G, Shen YC, Chen CH, Zhau YW, Silverman JM. A case-control study of Alzheimer's disease in China. Neurology 42:1481–1482, 1992.

80. Mylly Kangas-Lousu Jarvi R, Isomaki H. Alzheimer's disease and rheumatoid arthritis. Br J Rheumatol 33:501–502, 1994.

81. Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C, Brandt J. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 45:51–55, 1995.

82. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ. A controlled trial of selegiline, α-tocopherol, or both as treatment for Alzheimer's disease. N Eng J Med 336:1216–1222, 1997.